Study raises doubts on value of additional imaging before colorectal cancer surgery

Among patients with a certain type of colorectal cancer with limited spread to the liver, imaging using positron emission tomography (PET) and computed tomography (CT) before surgery did not significantly change the surgical treatment of the cancer, compared with CT alone, according to a new study.

Colorectal cancer is a leading cause of cancer death. Approximately 50% of patients present with or subsequently develop cancer that has spread to the liver. Some patients with liver metastases are candidates for surgery to have the cancer removed.

However, unidentified occult (hidden) metastases at the time of surgery can render the operation noncurative. Thus, long-term survival following surgical resection for colorectal cancer liver metastases is only about 50%. PET combined with CT could help avoid noncurative surgery by identifying patients with occult metastases, according to background information in the article.

 Carol-Anne Moulton, MB, BS, of the University Health Network, Toronto, Canada, and colleagues randomly assigned patients with colorectal cancer treated by surgery with resectable metastases based on CT scans to undergo PET-CT (n = 270) or CT only (n = 134) to determine the effect on the surgical management of these patients. The study, conducted between 2005 and 2013, involved 21 surgeons at 9 hospitals in Ontario.

Of the 263 patients who received PET-CT scans, 111 provided new information: 62 were classified as negative, and 49 had abnormal or suspicious lesions. Change in management (canceled, more extensive liver surgery, or surgery performed on additional organs) as a result of the PET-CT findings occurred in 8.7% of cases; 2.7% avoided noncurative liver surgery. Overall, liver resection was performed on 91% of patients in the PET-CT group and 92% of the control group.

The median follow-up was 3 years. The researchers found no significant difference in survival or disease-free survival between patients in the PET-CT group vs the control group.

“Many countries struggle to maintain quality health care within existing budgets. This is difficult because of increasing health care costs as a result of an aging population and the expense of new therapies and technologies, including diagnostic and functional imaging,” the authors wrote in their research article, which was published in JAMA (2014; doi:10.1001/jama.2014.3740).

“Among patients with potentially resectable hepatic metastases of colorectal adenocarcinoma, the use of PET-CT compared with CT alone did not result in frequent change in surgical management. These findings raise questions about the value of PET-CT scans in this setting.”

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs